Biogen [BIIB] vs Eli Lilly and [LLY] Detailed Stock Comparison
Biogen
NASDAQ
Loading...
Eli Lilly and
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Biogen wins in 9 metrics, Eli Lilly and wins in 10 metrics, with 0 ties. Eli Lilly and appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Biogen | Eli Lilly and | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 13.19 | 45.00 | Biogen |
| Price-to-Book Ratio | 1.15 | 33.86 | Biogen |
| Debt-to-Equity Ratio | 37.40 | 217.89 | Biogen |
| PEG Ratio | 8.27 | 0.49 | Eli Lilly and |
| EV/EBITDA | 7.50 | 26.96 | Biogen |
| Profit Margin (TTM) | 15.31% | 25.91% | Eli Lilly and |
| Operating Margin (TTM) | 34.61% | 45.81% | Eli Lilly and |
| EBITDA Margin (TTM) | 34.61% | 45.81% | Eli Lilly and |
| Return on Equity | 9.13% | 86.29% | Eli Lilly and |
| Return on Assets (TTM) | 5.62% | 16.55% | Eli Lilly and |
| Free Cash Flow (TTM) | $2.52B | $414.30M | Biogen |
| Dividend Yield | N/A | 0.52% | N/A |
| 1-Year Return | -32.14% | -25.50% | Eli Lilly and |
| Price-to-Sales Ratio (TTM) | 2.02 | 11.61 | Biogen |
| Enterprise Value | $24.16B | $667.81B | Eli Lilly and |
| EV/Revenue Ratio | 2.42 | 12.54 | Biogen |
| Gross Profit Margin (TTM) | 77.13% | 84.27% | Eli Lilly and |
| Revenue per Share (TTM) | $68 | $59 | Biogen |
| Earnings per Share (Diluted) | $10.45 | $15.33 | Eli Lilly and |
| Beta (Stock Volatility) | 0.13 | 0.44 | Biogen |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Biogen vs Eli Lilly and Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Biogen | 0.09% | 3.10% | 13.40% | 9.70% | -1.08% | -7.25% |
| Eli Lilly and | 0.62% | 3.71% | -6.87% | -2.09% | -18.76% | -8.77% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Biogen | -32.14% | -29.95% | -50.57% | -54.19% | 154.80% | 238.90% |
| Eli Lilly and | -25.50% | 124.94% | 381.76% | 753.25% | 1,975.50% | 1,229.00% |
Performance & Financial Health Analysis: Biogen vs Eli Lilly and
| Metric | BIIB | LLY |
|---|---|---|
| Market Information | ||
| Market Cap | $20.21B | $618.46B |
| Market Cap Category | Large cap | Mega cap |
| 10 Day Avg. Volume | 1,259,084 | 9,239,525 |
| 90 Day Avg. Volume | 1,387,041 | 5,536,438 |
| Last Close | $139.12 | $709.82 |
| 52 Week Range | $110.04 - $207.59 | $623.78 - $972.53 |
| % from 52W High | -32.98% | -27.01% |
| All-Time High | $480.18 (Mar 16, 2015) | $972.53 (Aug 19, 2024) |
| % from All-Time High | -71.03% | -27.01% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.07% | 0.38% |
| Quarterly Earnings Growth | 0.09% | 0.91% |
| Financial Health | ||
| Profit Margin (TTM) | 0.15% | 0.26% |
| Operating Margin (TTM) | 0.35% | 0.46% |
| Return on Equity (TTM) | 0.09% | 0.86% |
| Debt to Equity (MRQ) | 37.40 | 217.89 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $120.29 | $20.38 |
| Cash per Share (MRQ) | $18.82 | $3.95 |
| Operating Cash Flow (TTM) | $2.12B | $10.94B |
| Levered Free Cash Flow (TTM) | $2.27B | $-2,265,437,440 |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.52% |
| Last 12-Month Dividend | N/A | $4.10 |
Valuation & Enterprise Metrics Analysis: Biogen vs Eli Lilly and
| Metric | BIIB | LLY |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 13.19 | 45.00 |
| Forward P/E | 8.27 | 30.45 |
| PEG Ratio | 8.27 | 0.49 |
| Price to Sales (TTM) | 2.02 | 11.61 |
| Price to Book (MRQ) | 1.15 | 33.86 |
| Market Capitalization | ||
| Market Capitalization | $20.21B | $618.46B |
| Enterprise Value | $24.16B | $667.81B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 2.42 | 12.54 |
| Enterprise to EBITDA | 7.50 | 26.96 |
| Risk & Other Metrics | ||
| Beta | 0.13 | 0.44 |
| Book Value per Share (MRQ) | $120.29 | $20.38 |
Financial Statements Comparison: Biogen vs Eli Lilly and
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BIIB | LLY |
|---|---|---|
| Revenue/Sales | $2.43B | $12.73B |
| Cost of Goods Sold | $629.30M | $2.22B |
| Gross Profit | $1.80B | $10.50B |
| Research & Development | $434.10M | $2.73B |
| Operating Income (EBIT) | $625.20M | $5.41B |
| EBITDA | $831.80M | $5.92B |
| Pre-Tax Income | $311.20M | $3.46B |
| Income Tax | $70.70M | $696.80M |
| Net Income (Profit) | $240.50M | $2.76B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BIIB | LLY |
|---|---|---|
| Cash & Equivalents | $2.60B | $3.09B |
| Total Current Assets | $7.63B | $41.26B |
| Total Current Liabilities | $5.30B | $30.07B |
| Long-Term Debt | $4.87B | $34.50B |
| Total Shareholders Equity | $16.98B | $15.85B |
| Retained Earnings | $19.50B | $15.10B |
| Property, Plant & Equipment | $6.22B | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BIIB | LLY |
|---|---|---|
| Operating Cash Flow | $518.90M | $4.88B |
| Capital Expenditures | $-37.10M | $-1.51B |
| Free Cash Flow | $212.20M | $-1.60B |
| Debt Repayment | $0 | N/A |
| Common Stock Repurchase | N/A | $-1.20B |
Short Interest & Institutional Ownership Analysis
| Metric | BIIB | LLY |
|---|---|---|
| Shares Short | 3.96M | 7.17M |
| Short Ratio | 2.97 | 2.20 |
| Short % of Float | 0.03% | 0.01% |
| Average Daily Volume (10 Day) | 1,259,084 | 9,239,525 |
| Average Daily Volume (90 Day) | 1,387,041 | 5,536,438 |
| Shares Outstanding | 145.72M | 897.54M |
| Float Shares | 146.23M | 895.44M |
| % Held by Insiders | 0.00% | 0.00% |
| % Held by Institutions | 0.93% | 0.84% |
Dividend Analysis & Yield Comparison: Biogen vs Eli Lilly and
| Metric | BIIB | LLY |
|---|---|---|
| Last 12-Month Dividend | N/A | $4.10 |
| Last 12-Month Dividend Yield | N/A | 0.52% |
| 3-Year Avg Annual Dividend | N/A | $4.02 |
| 3-Year Avg Dividend Yield | N/A | 0.22% |
| 3-Year Total Dividends | N/A | $12.05 |
| Ex-Dividend Date | N/A | Feb 14, 2025 |